Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 31:6:232.
doi: 10.3389/fonc.2016.00232. eCollection 2016.

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Jérôme Fayette  1 , Lori Wirth  2 , Cristina Oprean  3 , Anghel Udrea  4 , Antonio Jimeno  5 , Danny Rischin  6 , Christopher Nutting  7 , Paul M Harari  8 , Tibor Csoszi  9 , Dana Cernea  10 , Paul O'Brien  11 , William D Hanley  12 , Amy V Kapp  12 , Maria Anderson  12 , Elicia Penuel  12 , Bruce McCall  12 , Andrea Pirzkall  12 , Jan B Vermorken  13
Affiliations

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Jérôme Fayette et al. Front Oncol. .

Abstract

Background: Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), inhibits signaling from all ligand-dependent HER dimers, and can elicit antibody-dependent cell-mediated cytotoxicity. High tumor-expression of neuregulin 1 (NRG1), a ligand to HER3, may enhance sensitivity to duligotuzumab.

Methods: This multicenter, open-label, randomized phase II study (MEHGAN) evaluated drug efficacy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) progressive on/after chemotherapy and among patients with NRG1-high tumors. Patients received duligotuzumab (1100 mg IV, q2w) or cetuximab (400 mg/m2 load, 250 mg/m2 IV, q1w) until progression or intolerable toxicity. Tumor samples were assayed for biomarkers [NRG1, ERBB3, and human papillomavirus (HPV) status].

Results: Patients (N = 121) were randomized (duligotuzumab:cetuximab; 59:62), median age 62 years; ECOG 0-2. Both arms (duligotuzumab vs. cetuximab, respectively) showed comparable progression-free survival [4.2 vs. 4.0 months; HR: 1.23 (90% confidence interval (CI): 0.89-1.70)], overall survival [7.2 vs. 8.7 months; HR 1.15 (90% CI: 0.81-1.63)], and objective response rate (12 vs. 14.5%), with no difference between patients with NRG1-high tumors or ERBB3-low tumors. Responses in both arms were confined to HPV-negative patients. Grade ≥3 adverse events (AEs) (duligotuzumab vs. cetuximab, respectively) included infections (22 vs. 11.5%) and GI disorders (17 vs. 7%), contributing to higher rates of serious AEs (41 vs. 29.5%). Metabolic disorders were less frequent with duligotuzumab (10 vs. 16%); any grade rash-related events were less with duligotuzumab (49 vs. 67%).

Conclusion: While several lines of preclinical evidence had supported the premise that the blockade of HER3 in addition to that of EGFR may improve outcomes for patients with R/M SCCHN overall or specifically in those patients whose tumors express high levels of NRG1, this study provided definitive clinical evidence refuting this hypothesis. Duligotuzumab did not improve patient outcomes in comparison to cetuximab despite frequent expression of NRG1. These data indicate that inhibition of EGFR alone is sufficient to block EGFR-HER3 signaling, suggesting that HER2 plays a minimal role in this disease. Extensive biomarker analyses further show that HPV-negative SCCHN but not HPV-positive SCCHN are most likely to respond to EGFR blockage by cetuximab or duligotuzumab.

Keywords: EGFR; HER3; HPV; MEHD7945A; NRG1; SCCHN; cetuximab; duligotuzumab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Duligotuzumab vs. cetuximab in intention to treat (ITT) population showing comparable antitumor activity. (A) Progression-free survival. (B) Overall survival.
Figure 3
Figure 3
ORR and treatment duration for primary treatment arms and crossover patients. (A) Duligotuzumab arm. (B) Cetuximab arm.
Figure 4
Figure 4
Efficacy relative to key biomarkers: (A) best change in target lesion sum of longest dimension (SLD) and corresponding NRG1, ERBB3, and HPV status; (B) PFS by NRG1 and ERBB3 expression levels by quartiles; and (C) NRG1 measured by qRT-PCR or by ISH does not predict response to duligotuzumab.
Figure 5
Figure 5
HER family ligand expression by HPV status. Ligand expression was higher in HPV-negative (−) subjects, with no responses in HPV-positive (+).
See this image and copyright information in PMC

Comment in

References

    1. Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med (2011) 12(66):419–32. - PMC - PubMed
    1. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol (2006) 24(17):2666–72.10.1200/jco.2005.04.8306 - DOI - PubMed
    1. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene (2006) 366(1):2–16.10.1016/j.gene.2005.10.018 - DOI - PubMed
    1. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol (2007) 25(16):2171–7.10.1200/jco.2006.06.7447 - DOI - PubMed
    1. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 359(11):1116–27.10.1056/NEJMoa0802656 - DOI - PubMed